Tenofovir-associated Fanconi syndrome: Review of the FDA adverse event reporting system

AIDS Patient Care and STDs

Volumn 22, Issue 2, 2008, Pages 99-103

  Gupta, Samir K ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACICLOVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; COTRIMOXAZOLE; DELAVIRDINE; DIDANOSINE; DOXORUBICIN; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; SULFADIAZINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG; VALACICLOVIR; ZIDOVUDINE;

ADOLESCENT; ADULT; AGED; AMINOACIDURIA; ARTICLE; BICARBONATE BLOOD LEVEL; CREATININE BLOOD LEVEL; DEMOGRAPHY; DIALYSIS; DISEASE SEVERITY; FANCONI RENOTUBULAR SYNDROME; FEMALE; FOOD AND DRUG ADMINISTRATION; FRACTURE; GLUCOSE URINE LEVEL; GLUCOSURIA; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; HYPOPHOSPHATEMIA; KIDNEY FAILURE; KIDNEY TUBULE ACIDOSIS; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; METABOLIC ACIDOSIS; NEPHROGENIC DIABETES INSIPIDUS; NEPHROTOXICITY; PATIENT MONITORING; POTASSIUM URINE LEVEL; PROTEINURIA; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; TREATMENT OUTCOME;

ADENINE; ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTI-HIV AGENTS; CHILD; FANCONI SYNDROME; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 39149101456     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2007.0052     Document Type: Article

References (19)

1. Panel on Clinical Practices for Treatment of HIV Infection. Department of Health and Human Services Guidelines for the use of antiretroviral in HIV-1-infected adults and adolescents. http://www.aidsinfo.nih.gov/guidelines (Last accessed October 26, 2006).
2. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292:191-201.
3. Butt AA. Tenofovir for chronic hepatitis B virus infection in HIV-coinfected patients. AIDS Reader 2006;16:219-222.
4. Rifkin BS, Perazella MA. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med 2004;117:282-284.
5. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: Three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003;36:1070-1073.
6. Earle KE, Seneviratne T, Shaker J, Shoback D. Fanconi's syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res 2004;19:714-721.
7. Padilla S, Gutierrez F, Masia M, Canovas V, Orozco C. Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: A case-control study. Aids Patient Care STDS 2005;19:421-424.
8. Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: A cohort and case-control study. J Acquir Immune Defic Syndr 2004;37:1489-1495.
9. Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr 2006;43:278-283.
10. Kaul S, Bassi K, Damle B, et al. Pharmacokinetic (PK) evaluation of the combination of atazanavir (ATV), enteric coated didanosine (ddi-EC), and tenofovir disoproxil fumarate (TDF) for a once-daily antiretrovirdal regimen. (A-1616). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: 2003.
11. Izzedine H, Hulot JS, Villard E, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006;194:1481-1491.
12. Cihlar T, Ho ES, Lin DC, Mulato AS. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 2001;20:641-648.
13. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006;50:3297-3304.
14. Cihlar T, Ray AS, Laflamme G, et al. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther 2007;12:267-272.
15. Kiser JJ, Aquilante CL, Anderson PL, Wolfe P, Carten ML, Fletcher CV. Effect of Multidrug resistance proteins 2 and 4 polymorphisms on tenofovir pharmacokinetics in HIV-infected patients (A34). 7th International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon, Portugal: 2006.
16. Cote HC, Magil AB, Harris M, et al. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Antivir Ther 2006;11:79-86.
17. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005;40:1194-1198.
18. Harris M, Zalunardo N, Bonner S, Werb R, Valyi M, Montaner JSG. Use of estimated glomerular filtration rate to predict renal toxicity in patients receiving tenofovir DF [Abstract 750]. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA: 2004.
19. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005;40:1559-1585.